Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 4
2014 4
2015 3
2016 7
2017 3
2018 1
2019 5
2020 3
2021 1
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
The adenosine pathway in immuno-oncology.
Allard B, Allard D, Buisseret L, Stagg J. Allard B, et al. Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. doi: 10.1038/s41571-020-0382-2. Epub 2020 Jun 8. Nat Rev Clin Oncol. 2020. PMID: 32514148 Review.
CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
Jacoberger-Foissac C, Cousineau I, Bareche Y, Allard D, Chrobak P, Allard B, Pommey S, Messaoudi N, McNicoll Y, Soucy G, Koseoglu S, Masia R, Lake AC, Seo H, Eeles CB, Rohatgi N, Robson SC, Turcotte S, Haibe-Kains B, Stagg J. Jacoberger-Foissac C, et al. Among authors: allard b. Cancer Immunol Res. 2023 Jan 3;11(1):56-71. doi: 10.1158/2326-6066.CIR-22-0260. Cancer Immunol Res. 2023. PMID: 36409930 Free PMC article.
Targeting the CD73-adenosine axis in immuno-oncology.
Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J. Allard D, et al. Among authors: allard b. Immunol Lett. 2019 Jan;205:31-39. doi: 10.1016/j.imlet.2018.05.001. Epub 2018 May 24. Immunol Lett. 2019. PMID: 29758241 Review.
Immunosuppressive activities of adenosine in cancer.
Allard B, Beavis PA, Darcy PK, Stagg J. Allard B, et al. Curr Opin Pharmacol. 2016 Aug;29:7-16. doi: 10.1016/j.coph.2016.04.001. Epub 2016 May 19. Curr Opin Pharmacol. 2016. PMID: 27209048 Review.
CD73-adenosine: a next-generation target in immuno-oncology.
Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. Allard D, et al. Among authors: allard b. Immunotherapy. 2016 Feb;8(2):145-63. doi: 10.2217/imt.15.106. Epub 2016 Jan 25. Immunotherapy. 2016. PMID: 26808918 Review.
Targeting the adenosine pathway for cancer immunotherapy.
Hammami A, Allard D, Allard B, Stagg J. Hammami A, et al. Among authors: allard b. Semin Immunol. 2019 Apr;42:101304. doi: 10.1016/j.smim.2019.101304. Semin Immunol. 2019. PMID: 31604539 Review.
CD73 Promotes Chronic Lymphocytic Leukemia.
Allard D, Chrobak P, Bareche Y, Allard B, Tessier P, Bergeron MA, Johnson NA, Stagg J. Allard D, et al. Among authors: allard b. Cancers (Basel). 2022 Jun 26;14(13):3130. doi: 10.3390/cancers14133130. Cancers (Basel). 2022. PMID: 35804900 Free PMC article.
On the mechanism of anti-CD39 immune checkpoint therapy.
Allard D, Allard B, Stagg J. Allard D, et al. Among authors: allard b. J Immunother Cancer. 2020 Feb;8(1):e000186. doi: 10.1136/jitc-2019-000186. J Immunother Cancer. 2020. PMID: 32098829 Free PMC article. Review.
35 results